{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:22:10Z","timestamp":1790817730036,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,10,3]],"date-time":"2012-10-03T00:00:00Z","timestamp":1349222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The current study investigated the efficacy, safety, tolerability, and compliance of a transdermal buprenorphine delivery system for the management of chronic cancer pain in the pediatric population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>Sixteen pediatric patients with moderate to severe cancer\u2010related pain not satisfactorily controlled with previous non\u2010opioid therapies were enrolled. Transdermal buprenorphine was administered following a 72\u2009hour schedule and rescue medication (tramadol) was allowed for breakthrough pain. Pain intensity was assessed using the Wong\u2013Baker faces pain rating scale (WBS) and other parameters related to the global quality of life were evaluated. Children's evaluations of efficacy, compliance, and tolerability were recorded using numerical scales. Adverse events were monitored during the study and the medications needed to control opioid\u2010related nausea and constipation were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eleven patients (68.75%) responded to transdermal buprenorphine after 2 weeks of treatment. Pain intensity measured with WBS decreased from 6.25 at baseline to 1.38 at Day +60 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). All outcome measures of global quality of life (quality of sleep, alimentation, play and activity, speech, and crying) significantly improved over the 60\u2010day study period. Children's evaluations of compliance and tolerability of the drug were always positive over the entire period of treatment. No severe adverse events were recorded. Opioid\u2010related nausea was well controlled with medication on request, and the need for laxative therapy was greater at the end of the second month of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Transdermal buprenorphine was found to represent an efficient, safe and well tolerated approach to the management of children's chronic cancer pain. Pediatr Blood Cancer 2013; 60: 433\u2013437. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.24332","type":"journal-article","created":{"date-parts":[[2012,10,3]],"date-time":"2012-10-03T15:15:24Z","timestamp":1349277324000},"page":"433-437","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and safety of transdermal buprenorphine in the management of children with cancer\u2010related pain"],"prefix":"10.1002","volume":"60","author":[{"given":"Antonio","family":"Ruggiero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Coccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Arena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palma","family":"Maurizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Battista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vita","family":"Ridola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Attin\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,10,3]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300251"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/ael051"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aei145"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-007-9440-z"},{"key":"e_1_2_5_6_2","first-page":"404","article-title":"Non peptide opioids: In vivo effects on the immune system","volume":"105","author":"Williams W","year":"1991","journal-title":"NIDA Res Monogfr"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(00)00198-3"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.04.020"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2006.02.044"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0929"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197917020-00001"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2005.12.001"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363190-00003"},{"key":"e_1_2_5_14_2","first-page":"2","article-title":"Old dog\u2014new matrix","volume":"90","author":"Budd K","year":"2003","journal-title":"Br J Anaesth"},{"key":"e_1_2_5_15_2","first-page":"233","volume-title":"Advances in pain research and therapy","author":"Caplan RA","year":"1990"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(04)03180-0"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1163\/156856903321579334"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)90019-1"},{"key":"e_1_2_5_19_2","first-page":"15","article-title":"The clinical development rationale and results","volume":"133","author":"Radbruch L","year":"2003","journal-title":"Int J Clin Pract Suppl"},{"key":"e_1_2_5_20_2","first-page":"13","article-title":"Efficacy and tolerability of buprenorphine TDS in cancer pain patients","volume":"10","author":"Radbruch L","year":"2003","journal-title":"Eur J Palliat Care"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.11.008"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21736"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00482-005-0428-5"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1191\/0269216304pm945rr"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-0683"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200002033420506"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2010.00378.x"},{"key":"e_1_2_5_28_2","first-page":"9","article-title":"Buprenorphine and the transdermal system: The ideal match in pain management","volume":"133","author":"Budd K","year":"2003","journal-title":"Int J Clin Pract Suppl"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9592.2010.03437.x"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363190-00003"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X53315"},{"key":"e_1_2_5_32_2","first-page":"115","article-title":"Transdermal buprenorphine in the management of persistent pain\u2010safety aspects","volume":"2","author":"Likar R","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21497"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24332","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24332","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.24332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T19:12:33Z","timestamp":1697656353000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.24332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1002\/pbc.24332"],"URL":"https:\/\/doi.org\/10.1002\/pbc.24332","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,3]]}}}